BiotechTube

Placebo + DISC-1459

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erythropoietic Protoporphyria (EPP)

Conditions

Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)

Trial Timeline

Apr 4, 2025 → Nov 1, 2026

NCT ID
NCT06910358

About Placebo + DISC-1459

Placebo + DISC-1459 is a phase 3 stage product being developed by Disc Medicine for Erythropoietic Protoporphyria (EPP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06910358. Target conditions include Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP).

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06910358Phase 3Recruiting

Competing Products

8 competing products in Erythropoietic Protoporphyria (EPP)

See all competitors
ProductCompanyStageHype Score
DISC-1459 + DISC-1459 + PlaceboDisc MedicinePhase 2
47
DISC-1459 + DISC-1459Disc MedicinePhase 2/3
60
AfamelanotideClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide 16mg implantClinuvel PharmaceuticalsPhase 1/2
33
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 2
44
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
69

Other Products from Disc Medicine

DISC-1459 + DISC-1459Phase 2/3
60
DISC-0974 + PlaceboPhase 2
47
DISC-1459 + DISC-1459 + PlaceboPhase 2
47
DISC-3405Phase 2
47
DISC-0974Phase 1/2
36